TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39319279
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg/day for patients previously diagnosed with GU and/or DU (Group 4)
Study: 39319356
Drug: Prescription Digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription Digital Therapeutic (PDT; Somryst)
Study: 39320397
Drug: Surgeon behaviors
Normalized name: sturgeon, unspecified preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeon behaviors (e.g., establishing rapport, providing reassuring information)
Study: 39320879
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with standardized tiered fever treatment on occurrence of temperature of 38 °C or greater.
Study: 39320906
Drug: Lenvatinib, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib, dosage and duration not specified
Study: 39320907
Drug: Crisugabalin 40
Normalized name: Crisugabalin
DrugBank: Crisugabalin (DB19300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisugabalin 40 mg/d
Study: 39320907
Drug: Crisugabalin 80
Normalized name: Crisugabalin
DrugBank: Crisugabalin (DB19300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisugabalin 80 mg/d
Study: 39321363
Drug: Tulisokibart (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulisokibart (1000 mg on day 1 and 500 mg at weeks 2, 6, and 10)
Study: 39321361
Drug: Ziresovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziresovir (10 to 40 mg, according to body weight), administered twice daily for 5 days
Study: 39321361
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice daily for 5 days
Study: 39321453
Drug: Web-based weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based weekly survey for out-of-pocket costs
Study: 39321757
Drug: Integrated Stepped
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Integrated Stepped Alcohol Treatment with Contingency Management (ISAT + CM)
Study: 39322237
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (n=189) - provided by GPs through brief counselling and psychotropic medication prescriptions
Study: 39322526
Drug: High remnant
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High remnant cholesterol (> 20.5 mg/dL; n = 1,116)
Study: 39322526
Drug: Intermediate remnant
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate remnant cholesterol (14‒20.5 mg/dL; n = 1,031)
Study: 39322526
Drug: Low remnant
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low remnant cholesterol (≤14.0 mg/dL; n = 1,201)
Study: 39322526
Drug: On-treatment remnant-C
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment remnant-C cut-off of 17 mg/dL (median)
Study: 39322526
Drug: Achieving LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieving LDL-C <55 or 70 mg/dL
Study: 39322802
Drug: CT-P17 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P17 (100 mg/mL), citrate-free adalimumab biosimilar
Study: 39322802
Drug: R-ADA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-ADA (100 mg/mL)
Study: 39322802
Drug: ADA-BioS (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA-BioS (50 mg/mL)
Study: 39322802
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with ADA-BioS
Study: 39322802
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with pain at injection site
Study: 39322802
Drug: CT-P17 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P17 treatment
Study: 39322961
Drug: Erenumab (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (70 mg or 140 mg) for migraine prophylaxis over 128 weeks.
Study: 39322961
Drug: Erenumab treatment
Normalized name: erenumab
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erenumab treatment after drug holiday.
Study: 39322961
Drug: Drug holiday
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug holiday (voluntary treatment interruption of up to 24 weeks).
Study: 39324933
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO2) treatment
Study: 39325452
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) - weekly group or individual counseling
Study: 39325452
Drug: Digital CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital CBT (CBT4CBT) plus brief weekly clinical monitoring
Study: 39325453
Drug: Tongxinluo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo (4 oral capsules, 3 times a day for 90 days)
Study: 39325453
Drug: Control (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo, 4 oral capsules, 3 times a day for 90 days)
Study: 39325463
Drug: Oral everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral everolimus 1.5-mg daily for 42 days after surgery
Study: 39325510
Drug: Ambulatory cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory cognitive tests administered via smartphone app 4 times per day during a 14-day data collection period.
Study: 39325643
Drug: Losartan 25-100
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 25-100 mg/day orally
Study: 39325787
Drug: Continued medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medical treatment of CRS
Study: 39326356
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume ≥7 mL/kg PBW
Study: 39326356
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume <7 mL/kg PBW
Study: 39326908
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (12 weeks)
Study: 39326908
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (APM and exercise therapy)
Study: 39326918
Drug: Selexipag (200-1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (200-1600 µg twice daily titration until individual maximum tolerated dose) + standard of care
Study: 39327056
Drug: Higher post-filter
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher post-filter ionised calcium target (0.35-0.45 mmol/L)
Study: 39327056
Drug: Lower post-filter
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower post-filter ionised calcium target (0.25-0.35 mmol/L)
Study: 39327294
Drug: Polypectomy repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypectomy repeated twice during the withdrawal phase after initial insertion of the colonoscope (study group).
Study: 39327433
Drug: Surufatinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib (200 mg, qd, po) plus toripalimab (240 mg, d1, ivdrip) combined with etoposide (100 mg/m², d1-d3, iv, drip) and cisplatin (25 mg/m², d1-d3, ivdrip)
Study: 39327563
Drug: One session
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One session of low-level laser therapy (LLLT) per week for 4 weeks
Study: 39327563
Drug: Two sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sessions of low-level laser therapy (LLLT) per week for 4 weeks
Study: 39327563
Drug: Three sessions
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sessions of low-level laser therapy (LLLT) per week for 4 weeks
Study: 39328096
Drug: Ritlecitinib 50
Normalized name: ritlecitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 50 or 30 mg (± 4-week 200-mg loading dose) for 24 weeks
Study: 39328096
Drug: Ritlecitinib 50
Normalized name: ritlecitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 50 or 30 mg for 24 weeks
Study: 39328391
Drug: Treatment expectation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment expectation measurements
Study: 39328832
Drug: Video-guided active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-guided active breaks through the 'Active Classes' web platform, lasting 5-10 minutes, moderate to vigorous intensity, twice a day, for 12 weeks.
Study: 39328960
Drug: Cannabis cream
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis cream
Study: 39329272
Drug: DNG/EE treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNG/EE treatment
Study: 39330494
Drug: Improvement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvement of glycemic control through medical intervention (insulin introduction, changes in multi-injection therapy, pump therapy introduction, therapeutic education)
Study: 39330966
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of PCV13
Study: 39330966
Drug: 40% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% dose of PCV13
Study: 39330966
Drug: 20% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% dose of PCV13
Study: 39330966
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of PCV10
Study: 39330966
Drug: 40% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% dose of PCV10
Study: 39330966
Drug: 20% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% dose of PCV10
Study: 39330966
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of PCV10 (three primary doses without a booster)
Study: 39330966
Drug: Vaccine-serotype carriage
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-serotype carriage
Study: 39331131
Drug: Anatomic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatomic treatment
Study: 39331218
Drug: topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical therapy or methotrexate
Study: 39331638
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg and 100 mg
Study: 39331724
Drug: Daratumumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab and lenalidomide (D-R) maintenance therapy
Study: 39331837
Drug: Everolimus (EVR)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVR) therapy
Study: 39331837
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EVR with decreased doses of calcineurin inhibitors (tacrolimus, cyclosporine)
Study: 39332395
Drug: Finerenone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (titrated to either 20 mg or 40 mg)
Study: 39332418
Drug: mRNA-1273.222 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273.222 (50 μg dose)
Study: 39332900
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) recanalization
Study: 39333450
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment after primary surgery
Study: 39333909
Drug: Anti-Spike IgG
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Spike IgG antibody levels in the control group
Study: 39333909
Drug: Anti-Spike IgG
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Spike IgG antibody levels in specific populations
Study: 39333909
Drug: Anti-RBD IgG
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-RBD IgG antibody levels in specific populations
Study: 39333909
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies in specific populations
Study: 39333988
Drug: Anlotinib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib at 12 mg once daily (QD) and S-1 at 60 mg twice daily (BID) for 2 weeks, followed by a 1-week treatment-free interval, then maintenance therapy with S-1 monotherapy at 60 mg BID for 2 weeks, followed by a 1-week treatment-free interval until disease progression.
Study: 39334042
Drug: Improvisational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvisational music therapy for 12 weeks
Study: 39334053
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (98.7% of patients) including risperidone (83.6%) with a mean dose of 8.0 ± 5.9 mg/day
Study: 39334053
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antipsychotics with benzodiazepines (34.5%)
Study: 39334053
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antipsychotics with antidepressants (14.4%)
Study: 39334053
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antipsychotics with antidepressants and benzodiazepines (25.9%)
Study: 39334053
Drug: Antipsychotic monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic monotherapy (17.9%)
Study: 39334120
Drug: Problem-solving-based psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving-based psychological intervention administered face-to-face (PSPI-P)
Study: 39334129
Drug: Bivalirudin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin plus a post-PCI high-dose infusion for 2-4 hours
Study: 39334129
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with bail-out GPI
Study: 39334205
Drug: Immunosuppressive or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive or cytotoxic therapy
Study: 39334218
Drug: Daily bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bilateral hamstring stretching exercises for six weeks
Study: 39334224
Drug: Goal-directed tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goal-directed tranexamic acid administration (Group-GDT)
Study: 39334224
Drug: Preemptive tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive tranexamic acid administration (Group-P)
Study: 39334260
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (AZI) 20 mg/kg bodyweight administered at 6 weeks, 9 months, and 15 months of age
Study: 39334260
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (AZI)
Study: 39337333
Drug: Tumor-infiltrating lymphocyte
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-infiltrating lymphocyte (TIL) therapy (lifileucel)
Study: 39337423
Drug: Nutraceutical supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical supplementation (olive (poly)phenol, vitamin C, and vitamin B preparation)
Study: 39339791
Drug: Daily orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily orange consumption, dosage not specified, duration not specified
Study: 39340109
Drug: B.1.351 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: B.1.351 vaccine
Study: 39340688
Drug: Colistin (CMS)
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistin (CMS) administered at a dosage of 6.75 MUI q12 after a 9 MIU loading dose.
Study: 39340691
Drug: Celecoxib plus
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib plus standard PD treatment (levodopa/carbidopa)
Study: 39340691
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD treatment (levodopa/carbidopa)
Study: 39340711
Drug: Finerenone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (10 mg and 20 mg)
Study: 39340758
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg orally for 26 weeks
Study: 39341405
Drug: N protein-based
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: N protein-based vaccine (50 µg)
Study: 39341482
Drug: Penn Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penn Medicine Healthy Heart intervention
Study: 39342463
Drug: SCH 727965
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 727965 (dinaciclib) 50 mg/m
Study: 39343051
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with 3 balloon dilations 3 weeks apart and/or needle-knife stricturotomy (NKSt)
Study: 39343051
Drug: Concurrent intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent intensified drug treatment
Study: 39343244
Drug: Oral nirmatrelvir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nirmatrelvir/ritonavir (NMV/r) 300/100 mg BID
Study: 39343244
Drug: Intravenous sotrovimab
Normalized name: sotrovimab
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intravenous sotrovimab (SOT)
Study: 39343244
Drug: Intramuscular tixagevimab/cilgavimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tixagevimab/cilgavimab (TGM/CGM)
Study: 39343247
Drug: NVX-CoV2373 (2-Dose)
Normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 (2-Dose) administered on day 0 and day 21
Study: 39343309
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of psilocybin
Study: 39343313
Drug: Internet-based interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based interpersonal psychotherapy (IPT) for 10 weeks with weekly therapist guidance
Study: 39343425
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks
Study: 39343510
Drug: Ipilimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (1 mg/kg intravenously every 6 weeks) plus Nivolumab (240 mg intravenously every 2 weeks)
Study: 39343865
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral pre-exposure prophylaxis pills
Study: 39343865
Drug: Monthly dapivirine
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dapivirine vaginal ring
Study: 39343942
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (weekly, supervised, 30-45 min sessions, encouraged to accumulate more than 5000 steps per day)
Study: 39344281
Drug: Ganaplacide 200
Normalized name: Ganaplacide
DrugBank: Ganaplacide (DB16173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaplacide 200 mg plus LUM-SDF 960 mg (run-in part)
Study: 39344366
Drug: Anticoagulant switching
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant switching
Study: 39344637
Drug: Colchicine treatment
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine treatment (exact dosage and duration not specified)
Study: 39344637
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (exact treatment not specified)
Study: 39345688
Drug: Oviderm® or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oviderm® or Canoderm® (intervention creams)
Study: 39345688
Drug: Decubal® lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decubal® lipid cream (comparator)
Study: 39345833
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral doses of 14,000 IU vitamin D
Study: 39346010
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation through a mid-gut tube
Study: 39346010
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation by oral administration
Study: 39347697
Drug: Mavacamten treatment
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mavacamten treatment for 26 weeks starting at 2.5 mg and potentially titrated up to 5 mg at week 14.
Study: 39348419
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies for dcSSc
Study: 39348472
Drug: Trebananib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib (30 mg/kg weekly) plus Pembrolizumab (200 mg every 3 weeks)
Study: 39348664
Drug: R-CHOP therapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 39348664
Drug: R-CHOP therapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP therapy
Study: 39348677
Drug: Weekly email
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly email newsletter (control)
Study: 39348705
Drug: <10 g/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: <10 g/dL transfusion strategy
Study: 39348705
Drug: <9 g/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: <9 g/dL transfusion strategy
Study: 39348705
Drug: <8 g/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: <8 g/dL transfusion strategy